NLS Pharmaceutics Shareholders Approve Merger with Kadimastem
Ticker: NCEL · Form: 6-K · Filed: Sep 30, 2025 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Sep 30, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: merger, shareholder-approval, press-release
TL;DR
NLS Pharma shareholders OK'd Kadimastem merger - deal is on!
AI Summary
On September 30, 2025, NLS Pharmaceutics Ltd. announced that its shareholders approved the merger with Kadimastem and related proposals at an Extraordinary General Meeting. This filing includes the press release detailing the shareholder vote.
Why It Matters
The shareholder approval is a critical step towards the completion of the merger between NLS Pharmaceutics and Kadimastem, potentially impacting the combined entity's future operations and market position.
Risk Assessment
Risk Level: medium — Merger approvals are significant events, but the actual success and integration of the merged companies carry inherent risks.
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Filing company
- Kadimastem (company) — Company to be merged with NLS Pharmaceutics
- September 30, 2025 (date) — Date of press release and shareholder meeting
FAQ
What was the primary purpose of the September 30, 2025, press release?
The press release announced that NLS Pharmaceutics shareholders approved the merger with Kadimastem and related proposals at an Extraordinary General Meeting.
Which company is NLS Pharmaceutics Ltd. merging with?
NLS Pharmaceutics Ltd. is merging with Kadimastem.
What type of meeting was held on September 30, 2025?
An Extraordinary General Meeting was held on September 30, 2025.
What is the filing number for this report?
The SEC file number is 001-39957.
Where is NLS Pharmaceutics Ltd. located?
NLS Pharmaceutics Ltd. is located at The Circle 6, 8058 Zurich, Switzerland.
Filing Stats: 207 words · 1 min read · ~1 pages · Grade level 11.7 · Accepted 2025-09-30 07:15:01
Filing Documents
- ea0259375-6k_nlspharma.htm (6-K) — 9KB
- ea025937501ex99-1_nlspharma.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 20KB
- 0001213900-25-093387.txt ( ) — 56KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: September 30, 2025 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3